Role of interleukin 6 in a murine model of Crohn's ileitis: Are cytokine/anticytokine strategies the future for IBD therapies?

Gut

Volumn 55, Issue 9, 2006, Pages 1226-1227

  Pizarro, T T ^a   De La Rue, S A ^a   Cominelli, F ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; GLYCOPROTEIN GP 130; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; MONOCLONAL ANTIBODY; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

CLINICAL TRIAL; CROHN DISEASE; DISEASE COURSE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG TARGETING; ENTERITIS; ENVIRONMENTAL FACTOR; GENE DELETION; GENE OVEREXPRESSION; HEREDITY; HUMAN; ILEITIS; IMMUNOREGULATION; INTRACELLULAR SPACE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; QUALITY OF LIFE; REVIEW; SIGNAL TRANSDUCTION; SMALL INTESTINE; ULCERATIVE COLITIS;

ANIMALS; CROHN DISEASE; DISEASE MODELS, ANIMAL; INTERLEUKIN-6; MICE; SIGNAL TRANSDUCTION;

EID: 33747801761     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2005.083121     Document Type: Review

References (20)

1. Pizarro TT, Arseneau KO, Bamias, et al. Mouse models for the study of Crohn's disease. Trends Mol Med 2003;9:218-22.
2. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol 2002;20:495-49.
3. Bahn AK, Mizoguchi E, Smith RN, et al. Colitis in transgenic and knockout animals as models of human inflammatory bowel disease. Immunol Rev 1999;169:195-07.
4. Kuhn R, Lohler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993;75:263-74.
5. Steidler L, Hans W, Schotte L, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000;289:1352-5.
6. Coombes JL, Robinson NJ, Maloy KJ, et al. Regulatory T cells and intestinal homeostasis. Immunol Rev 2005;204:184-94.
7. Matsumoto S, Okabe Y, Setoyama H, et al. Inflammatory bowel disease-like enteritis and caecitis in a senescence accelerated mouse P1/Yit strain. Gut 1998;43:71-8.
8. Strober W, Nakamura K, Kitani A. The SAMP1/Yit mouse: another step closer to modeling human inflammatory bowel disease. J Clin Invest 2001;107:667-70.
9. Kosiewicz MM, Nast CC, Krishnan A, et al. Th1-type responses mediate spontaneous ileitis in a novel murine model of Crohn's disease. J Clin Invest 2001;107:695-702.
10. Rivera-Nieves J, Bamias G, Vidrich A, et al. Emergence of perianal fistulizing disease in the SAMP1/YitFc mouse, a spontaneous model of chronic ileitis. Gastroenterology 2003;124:972-82.
11. Cominelli F. Cytokine-based therapies for Crohn's disease-new paradigms. N Engl J Med 2004;351:2045-8.
12. Korzenick JR, Dieckgraefe BK, Valentine JF, et al. Sargramostim for active Crohn's disease. N Engl J Med 2005;352:2193-201.
13. Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004;126:1593-610.
14. Feagan BG, Yan S, Bala M, et al. The effects of infliximab maintenance therapy on health-related quality of life. Am J Gastroenterol 2003;98:2232-8.
15. Sandborn WJ, Loftus EV. Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease. Gut 2004;53:780-2.
16. Isaacs KL, Lewis JD, Sandborn WJ, et al. State of the Art: IBD Therapy and Clinical Trials in IBD. Inflamm Bowel Dis 2005;11(suppl 1):S3-12.
17. Mitsuyama K, Matsumoto S, Rose-John S, et al. STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/Yit mice. Gut 2006;55:1263-9.
18. Yamamoto M, Yoshizaki K, Kishimoto T, et al. IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol 2000;164:4878-82.
19. Atreya R, Mudter J, Finotoo S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn's disease and experimental colitis in vivo. Nat Med 2000;6:583-8.
20. Ito H, Tazazoe M, Fukuda Y, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004;126:989-96.